Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

nted at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in October 2010. Clinical investigator Derrick Crook, M.D., presented data showing that CDI patients treated with fidaxomicin experienced 47% fewer recurrences than patients treated with vancomycin.
  • Five abstracts from Optimer's fidaxomicin Phase 3 studies in patients with CDI were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2010. Data from these abstracts highlighted that fidaxomicin was shown to be superior to vancomycin in treating CDI recurrences and reducing the chance of another relapse. Other conference presentations highlighted data showing that for patients taking concomitant antibiotics, fidaxomicin was a superior therapy to vancomycin in preventing recurrence and promoting global cure.
  • Entered into a long-term supply agreement with Biocon Limited for the commercial manufacture of the active pharmaceutical ingredient in fidaxomicin.
  • Pedro Lichtinger succeeded Michael N. Chang, Ph.D. as Optimer's President and Chief Executive Officer and also was appointed to the Board of Directors.  Dr. Chang was appointed Chairman of Optimer's Board of Directors. 
  • Top-line data from Optimer's second Phase 3 study of fidaxomicin was presented for the first time by clinical investigator, Derrick Crook, M.D., at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in April 2010. Dr. Crook also presented additional data on the strain type subgroups BI/NAP1/027 and non-BI/NAP1/027 which showed fidaxomicin had a clinically meaningful reduction in recurrence rates and higher global cure rates compared to vancomycin in both these subgroups. 
  • Announced positive results from the second Phase 3 trial of fidaxomicin in CDI confirming the results of our first Phase 3 trial. 91.7% of patients treated with fidaxomicin (per protocol population) achiev
    '/>"/>

  • SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
    9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
    10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
    11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Utah , July 10, 2014  BC Technical, ... and MiE America , Inc., a leading provider ... entered into a long-term agreement naming BC Technical as ... US. MiE and BC Technical announced ... agreement to establish BC Technical as the service and ...
    (Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
    (Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China ... store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... and policy support, China,s orthopedic ... with total market size rising from 3.28 billion yuan ...
    Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
    (Date:7/13/2014)... A Xarelto lawsuit webpage has been launched ... with the most current information regarding serious internal bleeding ... as well as the growing number of Xarelto ... The law firm is now offering free legal evaluations ... bleeding and related complications while using Xarelto, including:, ...
    (Date:7/13/2014)... (PRWEB) July 13, 2014 According to ... this is a comprehensive program that teaches people how ... peripheral neuropathy without medications. This program also provides ... symptoms of peripheral neuropathy , including numbness, prickling, burning, ... its review that this home treatment program can help ...
    (Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
    (Date:7/12/2014)... 12, 2014 The report, "Phthalic Anhydride ... Market by Application & Geography – Trends & Forecast ... analysis and forecasting of market volume and value. The ... derivatives separately. The market of phthalic anhydride is projected ... to $8,415.89 million by 2018, with a CAGR of ...
    (Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
    Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
    ... nearly 2 hours in the waiting room of the hospital, was ... ,Beatrice Vance, 49, died of a heart attack, but her death ... care that a reasonable person would have exercised in this situation.' ... Waukegan. A spokeswoman of that center refused to comment on the ...
    ... new backpack your son or daughter just got for the ... for a lifetime of back and neck ailments if not// ... of the Department of Occupational Therapy at University of the ... even they can’t take the day after day stress caused ...
    ... American inner city schoolgirls have been developing culturally ... measure// which children are likely to take offense ... the cartoons over traditional written descriptions of provocative ... Ph.D., a pediatric psychologist at The Children's Hospital ...
    ... and the American Society for Therapeutic Radiology and Oncology ... comes to// prostate cancer awareness, screening and their treatment ... cases of prostate cancer will be diagnosed in the ... screening for prostate cancer is relatively easy. ...
    ... to officials on Friday, a courthouse in New Jersey was ... the workers and it will remain shut at// least until ... of the woman’s medical condition, partly due to privacy rules. ... be critical. She is an independent title searcher with the ...
    ... new treatment for malaria has been developed with the help ... lives in Africa. A system based on fluid// replacement for ... College in London in collaboration with the Wellcome Trust Kenya ... lives of millions of kids, who die every year due ...
    Cached Medicine News:Health News:Lighten Up! Heavy Backpacks a Weighty Load for Children to Bear 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 3Health News:Do You Know the Signs and Symptoms of Prostate Cancer? 2Health News:A Novel approach in Malaria treatment 2
    Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
    ... The Diagnostic Automation, Inc.. (DAI) Measles ... for the detection and quantitative determination of ... human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
    ... osmolality at room temperature with the sample ... are cryoscopic artifacts due to high viscosity, ... with freezing point determinations. The superbly accurate ... osmometer has a much broader range of ...
    ... a glucocorticoid produced by the adrenal cortex ... is secreted with a circadian periodicity, and ... morning. Cortisol is often elevated in major ... AIDS, and in the visceral fat of ...
    Medicine Products: